Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)
As patients with multiple sclerosis (MS) age, the risk of cancer also increases. Immune checkpoint inhibitors (ICIs) are novel monoclonal antibodies that have revolutionized cancer treatment. However, their use is limited by immune related adverse events. In patients with MS and pre-existing autoimm...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925000364 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!